Red Ginseng for the Prevention of TC/TP chemotherapy-induced myelosuppression in Ovarian Cancer Patients

The University Branch of Guangdong Province Hospital of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1.Patients, between 30 and 70 years of age, diagnosed with ovarian cancer;
•2.Patients who have not received chemotherapy and who will undergo TC/TP chemotherapy;
•3.Patients who meet the diagnostic criteria of qi deficiency in TCM;
•4.Patients who voluntarily sign the informed consent to this trial and consent to participate in all visits as required.

•1.Patients who have hematologic diseases, such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenic purpura, bone marrow invasion of cancers and hypersplenism;
•2.Patients who have to use drugs which may cause changes in the blood cells, such as sulfonamides, certain non-steroidal anti-inflammatory drugs;
•3.Patients who allergy to multiple drugs;
•4.Patients with expected survival time less than 3 months;
•5.Patients with serious primary diseases, such as heart, brain, liver and hematopoietic system diseases;
•6.Uncooperative patients, such as patients with mental disorder;
•7.Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months;
•8.Patients have diseases or other conditions that will reduce the possibility of enrollment or complicate the enrollment.

发起方

The University Branch of Guangdong Province Hospital of Chinese Medicine